<DOC>
	<DOCNO>NCT01220232</DOCNO>
	<brief_summary>This open-label , fixed-sequence , multiple dose crossover study 14 healthy male and/or female subject , estimate effect steady state lersivirine steady state pharmacokinetics abacavir/lamivudine .</brief_summary>
	<brief_title>Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Healthy male and/or female subject . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 . Total body weight &gt; 50 kg ( 110 lb ) . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication . History hypersensitivity abacavir , lamivudine and/or lersivirine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Lersivirine</keyword>
	<keyword>UK-453</keyword>
	<keyword>061</keyword>
	<keyword>NNRTI</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Combivir</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug Interaction</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
</DOC>